Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ANGN

Angion Biomedica (ANGN) Stock Price, News & Analysis

Angion Biomedica logo

About Angion Biomedica Stock (NASDAQ:ANGN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.00
$10.00
52-Week Range
N/A
Volume
224,800 shs
Average Volume
86,718 shs
Market Capitalization
$30.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.

Receive ANGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter.

ANGN Stock News Headlines

Akari Therapeutics PLC ADR
OXBDF Oxford Biomedica plc
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLaren Engineering, a NASDAQ-listed marine tech company unveiled a groundbreaking new electric powertrain set to transform the industry.
8-K: Angion Biomedica Corp.
See More Headlines

ANGN Stock Analysis - Frequently Asked Questions

Angion Biomedica Corp. (NASDAQ:ANGN) released its quarterly earnings data on Friday, November, 12th. The company reported ($5.30) EPS for the quarter, topping analysts' consensus estimates of ($7.30) by $2.00. The company had revenue of $1.46 million for the quarter, compared to the consensus estimate of $1.08 million.

Angion Biomedica shares reverse split on Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Angion Biomedica (ANGN) raised $75 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Stifel acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Angion Biomedica investors own include Evofem Biosciences (EVFM), Plug Power (PLUG), CNS Pharmaceuticals (CNSP), Viking Therapeutics (VKTX), ContextLogic (WISH), Abeona Therapeutics (ABEO) and Applied Genetic Technologies (AGTC).

Company Calendar

Last Earnings
11/12/2021
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ANGN
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$38.81 million
Pretax Margin
-4,456.97%

Debt

Sales & Book Value

Annual Sales
$2.30 million
Price / Cash Flow
N/A
Book Value
$1.32 per share
Price / Book
N/A

Miscellaneous

Free Float
24,182,000
Market Cap
$30.11 million
Optionable
Not Optionable
Beta
0.60
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:ANGN) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners